Navigation Links
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
Date:9/15/2008

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.

"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."

Said Steven Tregay, PhD, a managing director of Novartis Option Fund, "We are impressed with both the quality and speed of the work that Cequent is doing on the IBD program -- as well as the potential of their tkRNAi platform. Creating compounds to address eight targets and completing in vitro screening in only nine months would have been virtually impossible with traditional small-molecule-based drug discovery technologies. We're pleased to release the milestone payment to Cequent, and look forward to our continued relationship both as venture
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
3. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
4. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
5. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
6. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
9. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
10. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
11. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Next month, executives from clinical trial marketing firm BBK Worldwide ... Patient-Centered Clinical Trials 2014 , to be held at ... September 4-5. Patient recruitment experts Bonnie A. Brescia , ... share insights on the benefits of employing an effective patient ... media to mobile apps – can be used to drive ...
(Date:8/28/2014)... a Florida State University research team has led to ... emit white light, and convert photon energy directly to ... butterfly. , Biwu Ma, associate professor in the Department ... of Engineering, created the molecule in a lab about ... his creation has many other unique capabilities. , For ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Reinforces Strategic Focus and Enhances Cash Position -, ... CALP ), a leading provider of tools and ... that it has,reached an agreement to sell its Pharmaceutical ... in a transaction valued at,approximately $15.8 million. The PDQ ...
... Board: TBIO) today announced financial results for the quarter,ended ... in,the tables that follow., Third Quarter 2008, ... the third,quarter of 2008, compared to $5.2 million during ... was $2.9 million or 54,percent during the third quarter ...
... Mass., Oct. 29 A US District Court,judge in ... Nephew (NYSE:,SNN; LSE: SN) Endoscopy,s request for an injunction ... from manufacturing or selling,medical devices that infringe a patent ... Hayhurst of Portland, Ore., A jury determined in ...
Cached Biology Technology:Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 2Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 3Transgenomic, Inc. Reports Third Quarter 2008 Results 2Transgenomic, Inc. Reports Third Quarter 2008 Results 3Transgenomic, Inc. Reports Third Quarter 2008 Results 4Transgenomic, Inc. Reports Third Quarter 2008 Results 5Transgenomic, Inc. Reports Third Quarter 2008 Results 6Transgenomic, Inc. Reports Third Quarter 2008 Results 7District Court Sides with Smith & Nephew; Rules that It will Issue Injunction that will Prohibit Arthrex Inc. from Selling Infringing Medical Devices 2District Court Sides with Smith & Nephew; Rules that It will Issue Injunction that will Prohibit Arthrex Inc. from Selling Infringing Medical Devices 3
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... force that a single fungal cell or bacterial colony exerts ... plays a heavy role in setting up some of the ... not be too much of a stretch to say that ... to respond to the touch of beneficial fungi, according to ... agronomy at the University of Wisconsin-Madison. , "Many people ...
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... WASHINGTON, D.C. (November 8, 2007)- There is a new reason ... of milk. Vitamin D, a key nutrient in milk, could ... new study published in the American Journal of Clinical Nutrition. ... twin pairs ages 19-79, British and American researchers found that ...
... Depending on its altitude, ozone can be either friend or foe. ... Western Ontario, scientists will now have a better understanding of ozone, ... plays in polluting our atmosphere. Ozone is a colourless, toxic ... pungent odour. In the stratosphere, acting ...
... ANGELES (November 7, 2007) FIJI Water, one of ... the world, announced a Sustainable Growth Initiative today that ... To achieve this, FIJI Water will account for ... products and then, through a combination of meaningful reductions ...
Cached Biology News:Could vitamin D, a key milk nutrient, affect how you age? 2Ozone intrusions -- humankind's fault? 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 3FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 4FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 5
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Antibodies were affinity purified using epitopes specific to UBAP2L/NICE4 immobilized on solid support....
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
Biology Products: